EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

High-risk pathogenic germline variants in blood relatives of BRCA1/2 negative probands

Reiko Yoshida, Tomoko Kaneyasu, Arisa Ueki, Hideko Yamauchi, Shozo Ohsumi, Shinji Ohno, Daisuke Aoki, Shinichi Baba, Junko Kawano, Naomichi Matsumoto, Masao Nagasaki, Takayuki Ueno und 14 weitere

Breast Cancer · 2024

DOI: 10.1007/s12282-024-01615-0 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Breast Cancer, 2024. Verfasst von Reiko Yoshida und 25 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cancer Genomics, Cancer Institute, Japanese Foundation for Cancer Research (JFCR), 3-8-31 Ariake, Koto-ku, Tokyo, Japan. Hauptthemen laut MEDLINE: Germ-Line Mutation, BRCA2 Protein, BRCA1 Protein, Genetic Predisposition to Disease. Die Arbeit nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Agency for Medical Research and Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Tailored, preventive cancer care requires the identification of pathogenic germline variants (PGVs) among potentially at-risk blood relatives (BRs). Cascade testing is carried out for BRs of probands who are positive for PGVs of an inherited cancer but not for negative probands. This study was conducted to examine the prevalence of PGVs for BRs of PGV-negative probands.

Methods

PGV prevalence was assessed for 682 BRs of 281 probands with BRCA1/BRCA2 wild-type hereditary breast and ovarian cancer (HBOC) syndrome.

Results

PGVs were discovered in 22 (45.8%) of the 48 BRs of the PGV-positive probands and in 14 (2.2%) of 634 BRs of the PGV-negative probands. Eleven PGVs on high-risk BRCA1 , BRCA2 , and TP53 genes were present only in BRs and not in the probands (probands vs BRs in Fisher exact test; p = 0.0104; odds ratio [OR] = 0.000 [0.000–0.5489 of 95% confidence interval]), partly due to the nature of the selection criteria. The enrichment of high-risk PGVs among BRs was also significant as compared with a non-cancer East Asian population ( p = 0.0016; OR = 3.0791 [1.5521–5.6694]). PGV prevalence, risk class of gene, and genotype concordance were unaffected by the cancer history among BRs.

Conclusion

These findings imply the necessity to construct a novel testing scheme to complement cascade testing.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Germ-Line MutationBRCA2 ProteinBRCA1 ProteinGenetic Predisposition to DiseaseHereditary Breast and Ovarian Cancer SyndromeHumansFemaleMiddle AgedAdultAgedGenetic TestingBreast NeoplasmsMalePedigreeFamilyTumor Suppressor Protein p53

Stichwörter der Autor:innen

Blood relative analysisCascade testingGenetic testingHereditary breast and ovarian cancer syndromePathogenic germline variant

Substanzen

BRCA2 protein, humanBRCA2 ProteinBRCA1 protein, humanBRCA1 ProteinTumor Suppressor Protein p53TP53 protein, human

Autor:innen und Institutionen

  • Division of Cancer Genomics, Cancer Institute, Japanese Foundation for Cancer Research (JFCR), 3-8-31 Ariake, Koto-ku, Tokyo, Japan.
  • Institute for Clinical Genetics and Genomics, Showa University, 1-5-8 Hatanodai, Shinagawa-ku, Japan.
  • Project for Development of Innovative Research on Cancer Therapeutics, Cancer Precision Medicine Center, Japanese Foundation for Cancer Research, Tokyo, 135-8550, Japan.
  • Department of Clinical Genetic Oncology, Cancer Institute Hospital, JFCR, 3-8-31 Ariake, Koto-ku, Tokyo, Japan.
  • Department of Breast Surgical Oncology, St. Luke's International Hospital, 10-1 Akashi-cho, Chuo-ku, Tokyo, Japan.
  • National Hospital Organization Shikoku Cancer Center, 160 Kou, Minamiumemoto-machi, Matsuyama, Ehime, Japan.

Förderung

  • Japan Agency for Medical Research and Development

Zitieren

APA

Yoshida, R., Kaneyasu, T., Ueki, A., Yamauchi, H., Ohsumi, S., Ohno, S., Aoki, D., Baba, S., Kawano, J., Matsumoto, N., Nagasaki, M., Ueno, T., Inari, H., Kobayashi, Y., Takei, J., Gotoh, O., Nishi, M., Okamura, M., Kaneko, K., …, & Nakamura, S. (2024). High-risk pathogenic germline variants in blood relatives of BRCA1/2 negative probands. Breast Cancer. https://doi.org/10.1007/s12282-024-01615-0

Vancouver

Yoshida R, Kaneyasu T, Ueki A, Yamauchi H, Ohsumi S, Ohno S, et al. High-risk pathogenic germline variants in blood relatives of BRCA1/2 negative probands. Breast Cancer. 2024. doi:10.1007/s12282-024-01615-0

BibTeX
@article{Yoshida2024,
  author = {Yoshida, Reiko and Kaneyasu, Tomoko and Ueki, Arisa and Yamauchi, Hideko and Ohsumi, Shozo and Ohno, Shinji and Aoki, Daisuke and Baba, Shinichi and Kawano, Junko and Matsumoto, Naomichi and Nagasaki, Masao and Ueno, Takayuki and Inari, Hitoshi and Kobayashi, Yusuke and Takei, Junko and Gotoh, Osamu and Nishi, Mitsuyo and Okamura, Miki and Kaneko, Keika and Okawa, Megumi and Suzuki, Misato and Amino, Sayuri and Inuzuka, Mayuko and Noda, Tetsuo and Mori, Seiichi and Nakamura, Seigo},
  title = {High-risk pathogenic germline variants in blood relatives of BRCA1/2 negative probands},
  journal = {Breast Cancer},
  year = {2024},
  doi = {10.1007/s12282-024-01615-0}
}
Kostenlos starten →